Ignite Creation Date:
2024-10-26 @ 3:41 PM
Last Modification Date:
2024-10-26 @ 3:41 PM
Study NCT ID:
NCT06619561
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-09-27
Brief Title:
A Phase 2 Study to Evaluate Vimseltinib in Adults with Active Chronic Graft-Versus-Host Disease cGVHD
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase 2 Open-label Multicenter Study to Evaluate the Safety Tolerability PK and Efficacy of Vimseltinib in Adults with Active Chronic GVHD After Failure of Prior Systemic Therapy
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine if vimseltinib is safe tolerable and works effectively to treat adults with active moderate to severe cGVHD Participants will be treated with vimseltinib in 28-day treatment cycles for approximately 2 years
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None